NCT03912883

Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,350 (estimated)
• Sponsor: Queen Mary University of London · Academic / Other
• Sex: Male
• Age: 18 Years – 76 Years
• Healthy volunteers: Not accepted

Summary

The Trans-Atlantic Prostate Group (TAPG) was established to examine the hypothesis that through a detailed retrospective analysis of outcome in a group of men with clinically localised prostate cancer at diagnosis, variables such as biological, pathological and clinical markers, could be identified that might accurately predict the prognosis of clinically localised prostate cancer.

Detailed description

In 1999, the TAPG group initiated the "Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting" study, referred to as the TAPG study. It is a retrospective population-based tissue sample study in men diagnosed with localised prostate cancer 1990-2006, inclusively. Initially the cohort comprised men diagnosed with prostate cancer with transurethral resection of the prostate (TURP) and needle biopsies 1990-1996, but was expanded from 2005 to include men diagnosed with prostate cancer 1990 - 2006. Data was collected from six regional cancer registries and eligibility was confirmed via hospital sites, which sent the relevant tissue samples to the TAPG Central Coordinating Office (CCO). Selection of eligible patients for the study completed in 2010. Since this year the TAPG CCO has been collecting cancer registration and mortality updates on the cohort members from regional cancer registries.

Conditions

• Prostate Cancer

Timeline

• Start date: 1999-10-12
• Primary completion: 2030-01-01
• Completion: 2030-01-01
• First posted: 2019-04-11
• Last updated: 2025-11-18